MILLENNIUM OUTBIDS GENZYME FOR CANADIAN BIOTECH ANORMED

Millennium Pharmaceuticals agreed to pay $515 million to acquire AnorMED, besting Genzyme's bid to buy the Canadian biotech firm. The deal gives Millennium rights to AnorMED's blood-cancer therapy Mozobil, which is in late-stage clinical trials. Wall Street Journal (http://users1.wsj.com/lmda/do/checkLogin?mg=wsj-users1&url=http%3A%2F%2Fonline.wsj.com%2Farticle%2FSB115931927250575082.html)